Beyond Air
Market Cap
US$119.1m
Last Updated
2020/07/03 00:22 UTC
Data Sources
Company Financials +
Executive Summary
Beyond Air, Inc., a clinical-stage medical device and biopharmaceutical company, develops inhaled nitric oxide (NO) to treat respiratory infections, and gaseous NO to treat solid tumors.
Snowflake Analysis
Flawless balance sheet with high growth potential.
Share Price & News
How has Beyond Air's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: XAIR's share price has been volatile over the past 3 months.
Market Performance
7 Day Return
0%
XAIR
4.4%
US Medical Equipment
1.6%
US Market
1 Year Return
28.9%
XAIR
6.1%
US Medical Equipment
4.8%
US Market
Return vs Industry: XAIR exceeded the US Medical Equipment industry which returned 6.1% over the past year.
Return vs Market: XAIR exceeded the US Market which returned 4.8% over the past year.
Shareholder returns
| XAIR | Industry | Market | |
|---|---|---|---|
| 7 Day | 0% | 4.4% | 1.6% |
| 30 Day | 0.4% | -0.04% | 2.3% |
| 90 Day | -23.7% | 22.3% | 29.5% |
| 1 Year | 28.9%28.9% | 7.0%6.1% | 7.1%4.8% |
| 3 Year | n/a | 57.6%53.2% | 37.1%28.1% |
| 5 Year | n/a | 107.6%91.4% | 67.2%48.6% |
Price Volatility Vs. Market
How volatile is Beyond Air's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall St
Beyond Air, Inc.'s (NASDAQ:XAIR) Shift From Loss To Profit2 months ago | Simply Wall St
What Type Of Shareholder Owns Beyond Air, Inc.'s (NASDAQ:XAIR)?3 months ago | Simply Wall St
Did You Miss Beyond Air's (NASDAQ:XAIR) 62% Share Price Gain?Valuation
Is Beyond Air undervalued compared to its fair value and its price relative to the market?
6.27x
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate XAIR's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate XAIR's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: XAIR is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.
PE vs Market: XAIR is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate XAIR's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: XAIR is overvalued based on its PB Ratio (6.3x) compared to the US Medical Equipment industry average (3.7x).
Next Steps
Future Growth
How is Beyond Air forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
63.9%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: XAIR is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.2%).
Earnings vs Market: XAIR is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: XAIR's is expected to become profitable in the next 3 years.
Revenue vs Market: XAIR's revenue (59.2% per year) is forecast to grow faster than the US market (9.3% per year).
High Growth Revenue: XAIR's revenue (59.2% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if XAIR's Return on Equity is forecast to be high in 3 years time
Next Steps
Past Performance
How has Beyond Air performed over the past 5 years?
-26.8%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: XAIR is currently unprofitable.
Growing Profit Margin: XAIR is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: XAIR is unprofitable, and losses have increased over the past 5 years at a rate of -26.8% per year.
Accelerating Growth: Unable to compare XAIR's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: XAIR is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (3.4%).
Return on Equity
High ROE: XAIR has a negative Return on Equity (-110.23%), as it is currently unprofitable.
Next Steps
Financial Health
How is Beyond Air's financial position?
Financial Position Analysis
Short Term Liabilities: XAIR's short term assets ($26.7M) exceed its short term liabilities ($4.9M).
Long Term Liabilities: XAIR's short term assets ($26.7M) exceed its long term liabilities ($4.5M).
Debt to Equity History and Analysis
Debt Level: XAIR's debt to equity ratio (25.8%) is considered satisfactory.
Reducing Debt: XAIR had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: XAIR has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: XAIR has sufficient cash runway for 1.3 years if free cash flow continues to reduce at historical rates of 24.9% each year.
Next Steps
Dividend
What is Beyond Air current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate XAIR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate XAIR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if XAIR's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if XAIR's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of XAIR's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
2.8yrs
Average management tenure
CEO
Steve Lisi (49yo)
3.08yrs
Tenure
US$1,268,835
Compensation
Mr. Steven Adam Lisi, also known as Steve, has been the Chief Executive Officer of Beyond Air, Inc. (formerly known as AIT Therapeutics, Inc.) since June 14, 2017. Mr. Lisi serves as Chief Executive Office ...
CEO Compensation Analysis
Compensation vs Market: Steve's total compensation ($USD1.27M) is above average for companies of similar size in the US market ($USD606.53K).
Compensation vs Earnings: Steve's compensation has been consistent with company performance over the past year.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Chairman of the Board | 3.08yrs | US$1.27m | 5.17% $6.2m | |
| Co-Founder | 3.5yrs | US$819.72k | 2.86% $3.4m | |
| Chief Financial Officer | 1.67yrs | US$406.25k | 0.092% $109.3k | |
| Chief Legal Officer & General Counsel | 2.33yrs | US$643.57k | no data | |
| Chief Commercial Officer | 1.5yrs | US$516.90k | 0.00059% $702.5 | |
| Senior VP of Clinical Research & Member of Scientific Advisory Board | no data | no data | no data | |
| Chief Medical Officer | 2.75yrs | no data | no data | |
| Senior Vice President of Device & Business Development | no data | no data | 0.17% $200.9k |
2.8yrs
Average Tenure
49yo
Average Age
Experienced Management: XAIR's management team is considered experienced (2.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Chairman of the Board | 3.08yrs | US$1.27m | 5.17% $6.2m | |
| Co-Founder | 3.5yrs | US$819.72k | 2.86% $3.4m | |
| Senior VP of Clinical Research & Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 2.5yrs | US$97.25k | 0.043% $50.9k | |
| Independent Director | 3.5yrs | US$97.25k | no data | |
| Member of Scientific Advisory Board | 2.5yrs | US$75.00k | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 2.92yrs | US$97.25k | 0.0069% $8.3k | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data |
3.0yrs
Average Tenure
50.5yo
Average Age
Experienced Board: XAIR's board of directors are considered experienced (3 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: XAIR insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 59.2%.
Top Shareholders
Company Information
Beyond Air, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Beyond Air, Inc.
- Ticker: XAIR
- Exchange: NasdaqCM
- Founded:
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: US$119.070m
- Shares outstanding: 16.84m
- Website: https://www.beyondair.net
Number of Employees
Location
- Beyond Air, Inc.
- 825 East Gate Boulevard
- Suite 320
- Garden City
- New York
- 11530
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| XAIR | NasdaqCM (Nasdaq Capital Market) | Yes | Common Stock | US | USD | Jan 2017 |
| 48L | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Jan 2017 |
Biography
Beyond Air, Inc., a clinical-stage medical device and biopharmaceutical company, develops inhaled nitric oxide (NO) to treat respiratory infections, and gaseous NO to treat solid tumors. The company is developing LungFit system, a NO generator and delivery system, which is in clinical trials for the treatment of lung infections, persistent pulmonary hypertension of the newborn, severe acute respiratory syndrome coronavirus 2, bronchiolitis, and nontuberculous mycobacteria.The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. The company is based in Garden City, New York.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/07/03 00:22 |
| End of Day Share Price | 2020/07/02 00:00 |
| Earnings | 2020/03/31 |
| Annual Earnings | 2020/03/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.